JPRN-UMIN000006914
Completed
未知
postmarketing surveillance For Investigating success in achieving clinical and functional Remission and Sustaining efficacy with Tocilizumab in BIOlogics naive RA patients - FIRST-BIO study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with rheumatoid arthritis who have been diagnosed based on the 2010 ACR/EULAR new classification criteria for RA Patients who have no previous medical history of biological agents for RA Patients whose disease activity is DAS28>
- Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Enrollment
- 700
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •No criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study To Evaluate The Safety And Efficacy Of Vfend® IV in Korean patientsEUCTR2017-000197-11-Outside-EU/EEAPfizer Inc.400
Completed
Phase 4
A post-marketing study of the marketed product Maxtra® P syrup for the evaluation of safety and effects in children having common cold.Health Condition 1: J00- Acute nasopharyngitis [common cold]CTRI/2021/02/031189Zuventus Healthcare Limited200
Completed
Phase 4
A post-marketing study of the marketed product Maxtra® P Tablets for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031390Zuventus Healthcare Limited200
Active, not recruiting
Not Applicable
reactogenicity and safety of Vaxem™HibMeningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2014-005203-24-Outside-EU/EEAovartis Vaccines and Diagnostics750
Active, not recruiting
Phase 4
A post-marketing surveillance study to evaluate the safety and immunological response of typhoid conjugate vaccine in healthy subjectsCTRI/2021/11/037996Cadila Healthcare Limited